Abstract
Venous thromboembolism (VT) is relatively common and serious treatment complication in women with gynecologic cancer. There are two subunits: deep venous thrombosis (DVT) and pulmonary embolism.
These complications significantly increase morbidity and decline the quality of life. Most important is direct or indirect impact on overall gynecologic cancer mortality.
There is a standard approach to use prophylactic low molecular weight heparins (LMWH) as VTE prevention in primary or secondary surgery during 5 to 10 days in our oncogynecological centers. Pelvic surgery is considered as high risk factor for VTE development.
There is an effort to identify high risk patient's group where long term 28 days prophylaxis could be a benefit. From gynecological cancers most risky are women with ovarian cancer, women after radical surgery with lymphadenectomy and women with neoadjuvant or adjuvant chemotherapy.
Optimal long term prophylaxis model is necessary to confirm by prospective studies in individual gynecologic cancers.